Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Abbott Labs

FedEx

Honeywell

Coca-Cola

Humana announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 26, 2024 to stockholders of record as of the close of business on March 29, 2024.

Daily Dividend Report: Humana, Fedex, Honeywell, Coca-Cola, Abbott

AT&T

The S&P 500 is riding a hot streak having recently closed above 5,000 for the first time ever, marking a new all-time high for the benchmark stock market index. So far this year, the S&P 500, which is comprised of the 500 largest publicly traded companies in America, is up 5%, building on a 24% gain achieved in 2023.

Exit Now! 3 S&P 500 Stocks to Sell in February 2024

Centene

Investors looking for stocks in the Medical - HMOs sector might want to consider either Centene (CNC) or Humana (HUM). But which of these two stocks presents investors with the better value opportunity right now?

CNC or HUM: Which Is the Better Value Stock Right Now?

Crocs

JPMorgan Chase & Co

In the past few years, there's no doubt that the technology industry has been booming. In 2022, the IT services market size was estimated to be $1.22 trillion and expected to continue growing at a CAGR of 9.7% from 2023 to 2030.

3 Non-Tech Stocks With Significant Momentum Potential

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM), a leading U.S. health insurer and healthcare services company, continues to make strides in advancing health equity by releasing the findings of its new pilot study published in the American Journal of Managed Care. Humana's screenings analysis marks the first study conducted by a national health plan, focusing on the often overlooked but critical aspects of structural determinants of health, like perceived discrimination and health lit.

Humana Releases Results from Innovative Health Literacy and Healthcare Discrimination Screenings Pilot

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Humana presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Humana Becomes Oversold

Humana Inc. investors have experienced a significant drop in the company's stock price, reaching lows not seen since January 2022, making a two-year round trip. The concerns over Humana's poor operating performance and shocking guidance for 2024 are justified, leading to the steep selloff. The company downgraded its 2024 outlook and stated that previous forecasts for 2025 are no longer achievable. As a result, growth-focused investors likely exited.

Humana: A Golden Buying Opportunity As Fears Potentially Peaked

Health insurance carrier Humana Inc. NYSE: HUM reported a bombshell when it released its fourth-quarter 2023 earnings report. The company not only missed its estimated EPS by a mile but also slashed its 2024 and 2025 EPS guidance by more than 50% to 75%, respectively.

Humana EPS shocker. Are Medicare Advantage plans in jeopardy?

Investors interested in stocks from the Medical - HMOs sector have probably already heard of Centene (CNC) and Humana (HUM). But which of these two stocks presents investors with the better value opportunity right now?

CNC vs. HUM: Which Stock Is the Better Value Option?

Humana's Q4 results fell well short of consensus and guidance for fiscal year 2024 is significantly lower, leading to an 11% drop in stock. Analysts were surprised by the big earnings per share miss and the lowered guidance, as other Medicare Advantage providers reported solid results and maintained their guidance. Humana's management cited increased medical costs and utilization of benefits as the primary factors for the poor earnings, and the company may need to raise rates to meet surging costs.

Humana, We Have A Problem

Total debit of $5.15 per set of contracts, based on recent trading, for this trade in Humana stock means the break-even cost stands at $375.15.

Humana Stock Today: After The Big Drop, Is It Time To Go Long With A Butterfly Call Spread?

Texas Instruments

The stock market might be at an all-time high, but that doesn't mean there aren't opportunities available to investors who want to buy low in the hopes of eventually selling high. In fact, one could argue that there are more deals to be had in the current market than at anytime in recent memory.

Buy the Dip! 3 Beaten-Down Stocks Poised for a Comeback.

Mesoblast

Multiplan Corp

Neogen

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That May Explode This Month - Mesoblast (NASDAQ:MESO), Humana (NYSE:HUM)

Humana announced a surprise quarterly loss on higher medical cost trends to end 2023. Management also issued disappointing forward earnings guidance.

Why Humana Stock Dropped Today

Humana (HUM) expects 2024 revenues to increase to around $113 billion.

Humana (HUM) Q4 Earnings Miss on Higher Costs, '25 Target Pulled

Humana Inc. (HUM) Q4 2023 Earnings Call Transcript

The medical cost increases reflect an increasing number of older adults returning to hospitals to undergo procedures they had delayed during the pandemic.

Humana stock plunges on dismal 2024 forecast, as insurers face soaring medical costs

While the top- and bottom-line numbers for Humana (HUM) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Humana (HUM) Q4 Earnings: A Look at Key Metrics

Humana (NYSE:HUM) shares tumbled more than 10% in early trade as the Kentucky-based health insurance firm warned its 2024 profits are expected to be impacted by higher costs associated with its Medicare Advantage offering. The company guided adjusted earnings per share (EPS) guidance of approximately $16, assuming higher Medicare Advantage costs experienced during the fourth quarter will persist throughout this year.

Humana issues 2024 profit warning amid rising costs; shares tumble

Humana (HUM) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $1.62 per share a year ago.

Humana (HUM) Reports Q4 Loss, Tops Revenue Estimates

The health insurer says 2024 earnings will be barely half of estimates due to higher Medicare Advantage costs.

Humana Dives On Huge 2024 Earnings Warning

Amgen

Cigna

Elevance Health Inc

Incyte

Sector components forecast to show the biggest earnings year-over-year earnings improvement include Humana Inc. NYSE: HUM, Elevance Health Inc. NYSE: ELV, Incyte Corp. NASDAQ: INCY, Insulet Corp. NASDAQ: PODD and Cigna Group NYSE: CI.

5 top healthcare stocks for earnings growth in 2024

Humana Inc.'s stock HUM, -1.26% fell 17% early Thursday, after the managed care company's quarterly loss widened amid soaring medial costs. Humana posted a loss of $491 million, or $4.42 a share, for the quarter, wider than the loss of $71 million, or 12 cents a share, posted in the year-earlier period.

Humana's stock tumbles 17% as quarterly loss widens amid soaring medical costs

Humana Inc forecast 2024 profit sharply below Wall Street estimates on Thursday as it expects higher costs within its Medicare Advantage plans for older adults to persist into 2024, sending the company's shares plunging 15% premarket.

Humana forecasts dismal 2024 profit on high medical costs

LOUISVILLE, Ky.--(BUSINESS WIRE)--Leading health insurer and health care services company Humana Inc. (NYSE: HUM) announced today that it has named David Dintenfass as President of Enterprise Growth. In this new role, Dintenfass will have responsibility for leading the company's growth plan with a primary focus on customer acquisition, retention, and experience. The creation of this position, and its emphasis on the customer and digital experience, will help Humana deliver on its long-term stra.

News for Humana Stock (HUM)